Humacyte Inc (HUMA) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Humacyte Inc   (NASDAQ: HUMA)


Humacyte Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Humacyte Inc 's ROA in the second quarter of 2026?
Humacyte Inc recorded a cumulative net loss of $-97 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -84.76%.

However, within the Healthcare sector 702 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4200, from total ROA ranking in the first quarter of 2026 at 4308.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -0.51 % -31.99 % -15.6 % -19.91 % 0.37 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -97 -98 -41 -37 -59
Return On Assets (TTM) -84.76 % -85.38 % -32.07 % -27.86 % -42.39 %
HUMA's Total Ranking # 4200 # 4308 # 3714 # 3986 # 4226
Total Assets (TTM) in million 138 111 116 92 139
Seq. Total Assets Change 24.9 % -4.99 % 27.16 % -34.07 % -14.62 %
Seq. Net Income Change - - - - -

HUMA's 5 Years Annual ROA >> Back to HUMA Management Effectiveness >> Compare HUMA ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 109
Sector # 703
Overall # 4158

Return On Assets Statistics
High Average Low
13.42 %
-55.44 %
-112.66 %
(Sep 30 2022)   (Sep 30 2024)



  News about Humacyte Inc Return on Assets ROA

Humacytes Revolutionary Breakthrough: A Double-Edged Sword Amidst Financial Struggles

In a significant advancement for vascular medicine, Humacyte Inc. has secured FDA approval for its innovative product, SYMVESS, an acellular tissue-engineered vessel designed specifically to treat extremity vascular trauma. Heralded as a first-in-class bioengineered human tissue, SYMVESS is designed to be a universally implantable vascular conduit aimed at improving the outcomes of arterial replacement and repair procedures. The implications of this breakthrough are vast, potentially transforming treatment paradigms in both civilian and military healthcare settings where vascular injury is prevalent.The announcement follows the publication of compelling study results in JAMA Surgery, where Humacyte s Acellular Tissue Engineered Vessel (ATEV) showcased promising outcomes in repairing arterial injuries, which are known to be prone to high rates of infection and complications. By replacing conventional synthetic grafts, the ATEV offers advantages including superior patency, enhanced limb salvage rates, and improved resistance to infection, which could significantly elevate standards in care for patients undergoing vascular repair.



Financial Statements
Humacyte Inc 's Assets $ 138 million HUMA's Balance sheet
Humacyte Inc 's Income $ -37 million Quarterly HUMA's Income Statement
HUMA's Income by Division See HUMA's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -15.6 % 7.53 % -37.22 % -28.68 % 43.95 %
Total Assets in million 116 138 128 204 286
Y / Y Net Income Change - - - - -
Net Income in million -41 -149 -111 -12 -26
Annual Return On Assets -35.09 % -107.85 % -86.39 % -5.86 % -9.25 %

HUMA's 5 Years Annual ROA >> Back to HUMA Management Effectiveness >> Compare HUMA ROA to its Competitors



More Return On Assets Ratios
HUMA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
HUMA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for HUMA's Competitors
Subscribers only: Roa for Humacyte Inc 's Suppliers
Subscribers only: Return On Assets for HUMA's Customers

You may also want to know
HUMA's Roi HUMA's Inventory Turnover Ratio HUMA's Growth Rates HUMA's Dividend Comparisons
HUMA's Profitability Ratios HUMA's Asset Turnover Ratio HUMA's Dividend Growth
HUMA's Roe HUMA's Valuation Ratios HUMA's Financial Strength Ratios HUMA's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:40:02+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.